Tsilimigras Diamantis I, Hyer J Madison, Diaz Adrian, Bagante Fabio, Ratti Francesca, Marques Hugo P, Soubrane Olivier, Lam Vincent, Poultsides George A, Popescu Irinel, Alexandrescu Sorin, Martel Guillaume, Workneh Aklile, Guglielmi Alfredo, Hugh Tom, Aldrighetti Luca, Endo Itaru, Pawlik Timothy M
Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Department of Surgery, University of Verona, 37134 Verona, Italy.
Cancers (Basel). 2021 Feb 11;13(4):747. doi: 10.3390/cancers13040747.
The prognostic role of tumor burden score (TBS) relative to pre-operative α -fetoprotein (AFP) levels among patients undergoing curative-intent resection of HCC has not been examined.
Patients who underwent curative-intent resection of HCC between 2000 and 2017 were identified from a multi-institutional database. The impact of TBS on overall survival (OS) and cumulative recurrence relative to serum AFP levels was assessed.
Among 898 patients, 233 (25.9%) patients had low TBS, 572 (63.7%) had medium TBS and 93 (10.4%) had high TBS. Both TBS (5-year OS; low TBS: 76.9%, medium TBS: 60.9%, high TBS: 39.1%) and AFP (>400 ng/mL vs. <400 ng/mL: 48.5% vs. 66.1%) were strong predictors of outcomes (both < 0.001). Lower TBS was associated with better OS among patients with both low (5-year OS, low-medium TBS: 68.0% vs. high TBS: 47.7%, < 0.001) and high AFP levels (5-year OS, low-medium TBS: 53.7% vs. high TBS: not reached, < 0.001). Patients with low-medium TBS/high AFP had worse OS compared with individuals with low-medium TBS/low AFP (5-year OS, 53.7% vs. 68.0%, = 0.003). Similarly, patients with high TBS/high AFP had worse outcomes compared with patients with high TBS/low AFP (5-year OS, not reached vs. 47.7%, = 0.015). Patients with high TBS/low AFP and low TBS/high AFP had comparable outcomes (5-year OS, 47.7% vs. 53.7%, = 0.24). The positive predictive value of certain TBS groups relative to the risk of early recurrence and 5-year mortality after HCC resection increased with higher AFP levels.
Both TBS and serum AFP were important predictors of prognosis among patients with resectable HCC. Serum AFP and TBS had a synergistic impact on prognosis following HCC resection with higher serum AFP predicting worse outcomes among patients with HCC of a certain TBS class.
尚未研究肿瘤负荷评分(TBS)相对于术前甲胎蛋白(AFP)水平在接受肝癌根治性切除的患者中的预后作用。
从一个多机构数据库中识别出2000年至2017年间接受肝癌根治性切除的患者。评估了TBS相对于血清AFP水平对总生存期(OS)和累积复发的影响。
在898例患者中,233例(25.9%)患者TBS低,572例(63.7%)患者TBS中等,93例(10.4%)患者TBS高。TBS(5年总生存率;低TBS:76.9%,中等TBS:60.9%,高TBS:39.1%)和AFP(>400 ng/mL与<400 ng/mL相比:48.5%与66.1%)都是预后的强预测因素(两者均<0.001)。在AFP水平低(5年总生存率,低-中等TBS:68.0%与高TBS:47.7%,<0.001)和高的患者中,较低的TBS与更好的总生存期相关(5年总生存率,低-中等TBS:53.7%与高TBS:未达到,<0.001)。与低-中等TBS/低AFP的个体相比,低-中等TBS/高AFP的患者总生存期更差(5年总生存率,53.7%与68.0%,P = 0.003)。同样,与高TBS/低AFP的患者相比,高TBS/高AFP的患者预后更差(5年总生存率,未达到与47.7%,P = 0.015)。高TBS/低AFP和低TBS/高AFP的患者预后相当(5年总生存率,47.7%与53.7%,P = 0.24)。某些TBS组相对于肝癌切除术后早期复发风险和5年死亡率的阳性预测值随着AFP水平升高而增加。
TBS和血清AFP都是可切除肝癌患者预后的重要预测因素。血清AFP和TBS对肝癌切除术后的预后有协同影响,较高的血清AFP预示着特定TBS类别的肝癌患者预后更差。